Hanmi/Aptose’s AML Contender Shows Early Promise

Oral Myeloid Kinome Inhibitor Set For Expansion Trials

Hanmi Pharmaceutical’s hopes for AML drug candidate HM43239, licensed out to Aptose Biosciences, are rising amid accumulating clinical data that appear to put the oral myeloid kinome inhibitor on the right track to registrational studies.

AML
Hanmi’s AML Candidate Nears Registrational Studies • Source: Shutterstock

A series of confirmed complete remissions at various doses in patients receiving Hanmi Pharmaceutical Co., Ltd.’s in-house-developed innovative drug for acute myeloid leukemia (AML), HM43239, are moving the once-daily, oral myeloid kinome inhibitor closer to registrational studies.

The drug is currently in an international Phase I/II trial in 34 patients with relapsed or refractory (R/R) AML who had received at least one prior line of therapy and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Anticancer

Ascentage Broadens Horizons As Pipeline Shows Renewed Promise

 
• By 

Ascentage will share at ASCO new clinical data on its Bcl-2 inhibitor lisaftoclax, part of the Chinese firm's novel pipeline, on which its CEO shared with Scrip plans and strategy, along with some views on the use of RWD in China.

Progress In The Effort To Improve Outcomes In SCLC

 

Several drug makers are working to bring new advances to small-cell lung cancer, a fast-growing cancer with limited treatment options.

Merus Bispecific Impresses In Head And Neck Cancer

 

Updated Phase II results from petosemtamab have impressed ahead of ASCO, outshining Keytruda monotherapy and its bispecific rival from Bicara.

Boehringer’s CMO On How AI, Integrated Evidence Generation Underpin Its Ambitious Launch Plans

 

The German company has big plans for the next five years or so. Scrip speaks to its chief medical officer Lykke Hinsch Gylvin about how it is using AI and other innovative approaches to make good on its ambitions.

More from Therapy Areas

Progress In The Effort To Improve Outcomes In SCLC

 

Several drug makers are working to bring new advances to small-cell lung cancer, a fast-growing cancer with limited treatment options.

GSK’s Nucala Set For Dupixent Face-Off After FDA COPD Nod

 
• By 

The UK major's asthma drug gets a key expanded approval.

Merus Bispecific Impresses In Head And Neck Cancer

 

Updated Phase II results from petosemtamab have impressed ahead of ASCO, outshining Keytruda monotherapy and its bispecific rival from Bicara.